Tirzepatide ODT

Tirzepatide ODT (orally disintegrating tablet)

Tirzepatide is a medication used for weight loss that acts as a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist. It mimics the effects of both hormones, which regulate appetite and glucose levels. By stimulating these receptors, tirzepatide helps reduce hunger, slow digestion, and increase insulin sensitivity, leading to significant weight loss and improved blood sugar control.

How Does Tirzepatide Work?

• Delays how quickly the stomach digests food, leading to a feeling of fullness and satisfaction with smaller meal sizes

• Stimulates insulin secretion by the pancreas

• Slows intestinal motility so you will feel fuller for longer after meals

• Lowers blood sugar, in part by reducing the production of glucose in the liver

• Decreases inflammation throughout the body, which leads to adiponectin release and fat lipolysis

Benefits of ODT

• Tablets are easy to take and are especially useful for patients who have an aversion to injections. 

• Administration allows the medication to be absorbed directly into the bloodstream through the mucous membranes under the tongue, bypassing the gastrointestinal tract and liver metabolism (first-pass effect).

• The ease of use and the faster onset of effects can lead to better adherence to the treatment regimen.

DOSING: The starting dose is 3mg daily for 30 days, followed by 4mg daily. You can titrate up to a max dose of 5mg daily.

STORAGE: Store this medication at 68°F to 77°F (20°C to 25°C) and away from heat, moisture and light.

Side Effects

Common Side Effects:

Nausea, vomiting, diarrhea, and constipation are common but usually decrease over time.

Serious Side Effects:

Seek medical attention if you experience symptoms of pancreatitis (severe abdominal pain), gallbladder problems, or allergic reactions (rash, itching, swelling, severe dizziness, trouble breathing).

WARNINGS:

Risk of Thyroid C-Cell Tumors: Tirzepatide, like other GLP-1 receptor agonists, has been shown to cause thyroid C-cell tumors in rodents. However, it is not known if this risk is applicable to humans. Nonetheless, caution is advised.

Contraindications: Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).